Biomarkers of Barrett’s Esophagus

From the Laboratory to Clinical Practice

Vani J.A. Konda, Rhonda F. Souza

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The currently recommended approach to managing cancer risk for patients with Barrett’s esophagus is endoscopic surveillance including a biopsy protocol to sample the esophageal tissue randomly to detect dysplasia. However, there are numerous limitations in this practice that rely on the histopathological grading of dysplasia alone to make clinical decisions. The availability of in silico models demonstrating the potential cost-effectiveness of biomarker-based stratification has increased interest in finding a clinically relevant “Barrett’s biomarker.” The success of endoscopic eradication therapy in preventing neoplastic progression of dysplastic Barrett’s esophagus has promoted the desire to stratify non-dysplastic Barrett’s esophagus to those with “high risk” that may benefit from endotherapy. Furthermore, on the other end of the spectrum, there is interest in searching for a “low risk” marker that may identify those that would not likely benefit from endoscopy screening or surveillance. This review highlights recent data from the genomics (r)evolution revealing new genetic biomarkers of susceptibility to the development of Barrett’s esophagus and novel pathways for its neoplastic progression, addresses the development of new modes of tissue sampling and imaging to detect early neoplasia in Barrett’s esophagus, and discusses current progress in moving biomarkers from the laboratory into clinical practice in the era of precision medicine.

Original languageEnglish (US)
Pages (from-to)2070-2080
Number of pages11
JournalDigestive Diseases and Sciences
Volume63
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Barrett Esophagus
Biomarkers
Precision Medicine
Genetic Predisposition to Disease
Genomics
Computer Simulation
Endoscopy
Cost-Benefit Analysis
Neoplasms
Biopsy

Keywords

  • Adenocarcinoma
  • Endoscopic imaging
  • Endotherapy
  • Genomics
  • Risk Stratification

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Biomarkers of Barrett’s Esophagus : From the Laboratory to Clinical Practice. / Konda, Vani J.A.; Souza, Rhonda F.

In: Digestive Diseases and Sciences, Vol. 63, No. 8, 01.08.2018, p. 2070-2080.

Research output: Contribution to journalReview article

@article{986b8689067f49e685f1e6518ff90cab,
title = "Biomarkers of Barrett’s Esophagus: From the Laboratory to Clinical Practice",
abstract = "The currently recommended approach to managing cancer risk for patients with Barrett’s esophagus is endoscopic surveillance including a biopsy protocol to sample the esophageal tissue randomly to detect dysplasia. However, there are numerous limitations in this practice that rely on the histopathological grading of dysplasia alone to make clinical decisions. The availability of in silico models demonstrating the potential cost-effectiveness of biomarker-based stratification has increased interest in finding a clinically relevant “Barrett’s biomarker.” The success of endoscopic eradication therapy in preventing neoplastic progression of dysplastic Barrett’s esophagus has promoted the desire to stratify non-dysplastic Barrett’s esophagus to those with “high risk” that may benefit from endotherapy. Furthermore, on the other end of the spectrum, there is interest in searching for a “low risk” marker that may identify those that would not likely benefit from endoscopy screening or surveillance. This review highlights recent data from the genomics (r)evolution revealing new genetic biomarkers of susceptibility to the development of Barrett’s esophagus and novel pathways for its neoplastic progression, addresses the development of new modes of tissue sampling and imaging to detect early neoplasia in Barrett’s esophagus, and discusses current progress in moving biomarkers from the laboratory into clinical practice in the era of precision medicine.",
keywords = "Adenocarcinoma, Endoscopic imaging, Endotherapy, Genomics, Risk Stratification",
author = "Konda, {Vani J.A.} and Souza, {Rhonda F.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s10620-018-5088-2",
language = "English (US)",
volume = "63",
pages = "2070--2080",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Biomarkers of Barrett’s Esophagus

T2 - From the Laboratory to Clinical Practice

AU - Konda, Vani J.A.

AU - Souza, Rhonda F.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The currently recommended approach to managing cancer risk for patients with Barrett’s esophagus is endoscopic surveillance including a biopsy protocol to sample the esophageal tissue randomly to detect dysplasia. However, there are numerous limitations in this practice that rely on the histopathological grading of dysplasia alone to make clinical decisions. The availability of in silico models demonstrating the potential cost-effectiveness of biomarker-based stratification has increased interest in finding a clinically relevant “Barrett’s biomarker.” The success of endoscopic eradication therapy in preventing neoplastic progression of dysplastic Barrett’s esophagus has promoted the desire to stratify non-dysplastic Barrett’s esophagus to those with “high risk” that may benefit from endotherapy. Furthermore, on the other end of the spectrum, there is interest in searching for a “low risk” marker that may identify those that would not likely benefit from endoscopy screening or surveillance. This review highlights recent data from the genomics (r)evolution revealing new genetic biomarkers of susceptibility to the development of Barrett’s esophagus and novel pathways for its neoplastic progression, addresses the development of new modes of tissue sampling and imaging to detect early neoplasia in Barrett’s esophagus, and discusses current progress in moving biomarkers from the laboratory into clinical practice in the era of precision medicine.

AB - The currently recommended approach to managing cancer risk for patients with Barrett’s esophagus is endoscopic surveillance including a biopsy protocol to sample the esophageal tissue randomly to detect dysplasia. However, there are numerous limitations in this practice that rely on the histopathological grading of dysplasia alone to make clinical decisions. The availability of in silico models demonstrating the potential cost-effectiveness of biomarker-based stratification has increased interest in finding a clinically relevant “Barrett’s biomarker.” The success of endoscopic eradication therapy in preventing neoplastic progression of dysplastic Barrett’s esophagus has promoted the desire to stratify non-dysplastic Barrett’s esophagus to those with “high risk” that may benefit from endotherapy. Furthermore, on the other end of the spectrum, there is interest in searching for a “low risk” marker that may identify those that would not likely benefit from endoscopy screening or surveillance. This review highlights recent data from the genomics (r)evolution revealing new genetic biomarkers of susceptibility to the development of Barrett’s esophagus and novel pathways for its neoplastic progression, addresses the development of new modes of tissue sampling and imaging to detect early neoplasia in Barrett’s esophagus, and discusses current progress in moving biomarkers from the laboratory into clinical practice in the era of precision medicine.

KW - Adenocarcinoma

KW - Endoscopic imaging

KW - Endotherapy

KW - Genomics

KW - Risk Stratification

UR - http://www.scopus.com/inward/record.url?scp=85050379567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050379567&partnerID=8YFLogxK

U2 - 10.1007/s10620-018-5088-2

DO - 10.1007/s10620-018-5088-2

M3 - Review article

VL - 63

SP - 2070

EP - 2080

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 8

ER -